Program
corabotase
Also written as “Corabotase”, “Corabotase dose A” and “Corabotase dose B”.
Its studies are mostly in Migraine Disorders · Torticollis, led by Ipsen.
Furthest: phase 3, since Feb 17, 20266 company-led studies, 6 open or runningNext primary completion: Dec 15, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ipsen | 66 open or running | phase 3since Feb 17, 2026 | Mar 26, 2021 | Dec 15, 2026phase 3 · NCT07435428 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 26, 2021First study: phase 2 study in Moderate to Severe Upper Facial LinesFirst studyNCT04821089 · 727 enrolled · France, Germany
- Oct 1, 2024Phase 2 study in Episodic MigraineNCT06625060 · 670 enrolled · United States, Australia, Brazil and more
- Apr 14, 2025Phase 2 study in TorticollisNCT06937931 · 132 planned · United States, Czechia, France and more
- Feb 17, 20262 phase 3 studies in Moderate to Severe Glabellar LinesPhase 3 reachedNCT07435428, NCT07427797
- Aug 19, 2026Phase 3 study in Moderate to Severe Glabellar LinesNCT07779252 · 160 planned · China
- Oct 6, 2026Primary completion moved from 2026-08-31 to 2027-08-19Date moved laterphase 2 · +12 months · NCT04821089
Ahead
- Dec 15, 2026Primary completion: phase 3 study in Moderate to Severe Glabellar LinesNCT07435428
- Dec 15, 2026Primary completion: phase 3 study in Moderate to Severe Glabellar LinesNCT07427797
- Mar 26, 2027Primary completion: phase 2 study in TorticollisNCT06937931
- Aug 19, 2027Primary completion: phase 2 study in Moderate to Severe Upper Facial LinesNCT04821089
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07779252Moderate to Severe Glabellar Lines · China | 3 | Recruiting | Apr 10, 2028 | 160 |
| NCT07435428Moderate to Severe Glabellar Lines · United States, France, Germany and more | 3 | Active, not recruiting | Dec 15, 2026 | 1,300 |
| NCT07427797Moderate to Severe Glabellar Lines · United States, Canada | 3 | Active, not recruiting | Dec 15, 2026 | 309 |
| NCT06937931Torticollis · United States, Czechia, France and more | 2 | Recruiting | Mar 26, 2027 | 132 |
| NCT06625060Episodic Migraine · United States, Australia, Brazil and more | 2 | Active, not recruiting | Oct 31, 2027 | 670 |
| NCT04821089Moderate to Severe Upper Facial Lines · France, Germany | 2 | Active, not recruiting | Aug 19, 2027 | 727 |
How it is read
Names in the registry
- “Corabotase”, 6 entries
- “Corabotase dose A”, 1 entry
- “Corabotase dose B”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 1 study
- Torticollis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.